Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691255 | 0.86 | TOP2A (0.45) | SMN1; SMN2ALDH1A1TDP1RECQLKDM4E | |
| SCHEMBL28556808 | 0.82 | TSHR (0.45) | TSHRSMN1; SMN2ALDH1A1ADRA2BPTGS1 | |
| SCHEMBL6813947 | 0.82 | TSHR (0.45) | TSHRSMN1; SMN2ALDH1A1ADRA2BPTGS1 | |
| SCHEMBL10521757 | 0.81 | TSHR (0.44) | TSHRSMN1; SMN2ALDH1A1ADRA2BPTGS1 | |
| SCHEMBL362721 | 0.81 | ALDH1A1 (0.52) | TSHRSMN1; SMN2ALDH1A1ADRA2BPTGS1 | |
| SCHEMBL11223702 | 0.80 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1TDP1RECQLLMNA | |
| SCHEMBL10522017 | 0.79 | TSHR (0.43) | TSHRSMN1; SMN2ALDH1A1ADRA2BPTGS1 | |
| SCHEMBL6894551 | 0.79 | SMN1; SMN2 (0.43) | TSHRSMN1; SMN2ALDH1A1ADRA2BPTGS1 | |
| SCHEMBL31656250 | 0.79 | ALDH1A1 (0.50) | TSHRSMN1; SMN2ALDH1A1ADRA2BPTGS1 | |
| SCHEMBL10522035 | 0.79 | TSHR (0.43) | TSHRSMN1; SMN2ALDH1A1ADRA2BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-09-29 | — | — | US | disclosed |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-09-29 | — | — | US | disclosed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | disclosed |
| WO-2012151440-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012088314-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | PDK2, PDK1, PDK3 | TSHR 1075/4885SMN1; SMN2 4500/4885ALDH1A1 1184/4885 |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | PDK1, PDK2, PCK1 | TSHR 1478/4885SMN1; SMN2 3053/4885ALDH1A1 1936/4885 |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | PCK1, PDK2, PFKP | TSHR 2197/4885SMN1; SMN2 3273/4885ALDH1A1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.